Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is funded by PER®.

Progress and Challenges in Non–Small Cell Lung Cancer and Colorectal Cancer With Pan-KRAS Inhibitors

Release Date: October 22, 2020
Expiration Date: October 22, 2021

Activity Overview

This continuing medical education (CME) activity is designed to inform health care providers involved in the clinical care of patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) of emerging therapies that target oncogenic KRAS mutations. Investigational KRAS inhibition agents currently undergoing evaluation in clinical trials include direct inhibitors of KRAS and inhibitors of upstream or downstream targets of the KRAS pathway. The in-depth program will cover recent updates regarding clinical trials investigating KRAS inhibitors for the treatment of NSCLC and CRC, including key data and their potential clinical implications for the therapeutic landscape of patients with NSCLC and CRC.

Acknowledgement of Commercial Support

This activity is funded by PER®.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain the differences between pan-KRAS and selective KRAS inhibition and how this could affect clinical activity
  • Evaluate efficacy and safety from clinical trials of pan-KRAS inhibitors in NSCLC and CRC
  • Describe the rationale for using pan-KRAS inhibitors individually and in combination for treating NSCLC and CRC

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Jonathan W. Riess, MD, MS
Jonathan W. Riess, MD, MS
Associate Professor of Medicine
Department of Internal Medicine
Division of Hematology & Oncology
UC Davis Comprehensive Cancer Center
Sacramento, CA

Disclosures: Grant/Research Support: Merck, Novartis, Spectrum, Revolution Medicine, AstraZeneca. Consultant: Novartis, Boehringer Ingelheim, Medtronic, Blueprint.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

This activity was written by PER® editorial staff under faculty guidance and review. The Q&A portion of the activity was transcribed from a recorded interview with the faculty and edited by faculty and PER® editorial staff for clarity.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By